326 related articles for article (PubMed ID: 16457698)
1. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.
Schindlbeck C; Kampik T; Janni W; Rack B; Jeschke U; Krajewski S; Sommer H; Friese K
Breast Cancer Res; 2005; 7(6):R1174-85. PubMed ID: 16457698
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
Schindlbeck C; Janni W; Shabani N; Rack B; Gerber B; Schmitt M; Harbeck N; Sommer H; Braun S; Friese K
Breast Cancer Res Treat; 2004 Sep; 87(1):65-74. PubMed ID: 15377852
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Krajewski S; Sommer H; Friese K
Breast Cancer Res Treat; 2007 Jan; 101(1):17-25. PubMed ID: 16807671
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
5. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
[TBL] [Abstract][Full Text] [Related]
6. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
7. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
9. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
10. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
Solomayer EF; Becker S; Pergola-Becker G; Bachmann R; Krämer B; Vogel U; Neubauer H; Wallwiener D; Huober J; Fehm TN
Breast Cancer Res Treat; 2006 Jul; 98(2):179-84. PubMed ID: 16552629
[TBL] [Abstract][Full Text] [Related]
11. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer.
Fehm T; Becker S; Pergola-Becker G; Krämer B; Gruber I; Sotlar K; Kurek R; Wallwiener D; Solomayer E
Anticancer Res; 2004; 24(6):4211-6. PubMed ID: 15736474
[TBL] [Abstract][Full Text] [Related]
12. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
[TBL] [Abstract][Full Text] [Related]
13. Micrometastasis in breast cancer and other solid tumors.
Pantel K; Woelfle U
J Biol Regul Homeost Agents; 2004; 18(2):120-5. PubMed ID: 15471214
[TBL] [Abstract][Full Text] [Related]
14. Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma.
Buchner A; Riesenberg R; Kotter I; Hofstetter A; Stief C; Oberneder R
Cancer; 2006 Apr; 106(7):1514-20. PubMed ID: 16518813
[TBL] [Abstract][Full Text] [Related]
15. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
Janni W; Rack B; Schindlbeck C; Strobl B; Rjosk D; Braun S; Sommer H; Pantel K; Gerber B; Friese K
Cancer; 2005 Mar; 103(5):884-91. PubMed ID: 15666325
[TBL] [Abstract][Full Text] [Related]
16. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
17. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
[TBL] [Abstract][Full Text] [Related]
18. Expression of HER2 and its association with AP-2 in breast cancer.
Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
[TBL] [Abstract][Full Text] [Related]
19. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Balic M; Lin H; Young L; Hawes D; Giuliano A; McNamara G; Datar RH; Cote RJ
Clin Cancer Res; 2006 Oct; 12(19):5615-21. PubMed ID: 17020963
[TBL] [Abstract][Full Text] [Related]
20. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
